From his low-security prison in Pennsylvania, former pharmaceutical executive and so-called “Pharma Bro” Martin Shkreli this week continued to seek a reduction in his sentence, arguing that his confinement prevents him from mounting an effective defense in a “fast-paced and complex” civil suit brought by the Federal Trade Commission.

In a reply letter to U.S. District Judge Kiyo Matsumoto Thursday, Shkreli’s attorney, Benjamin Brafman of Brafman & Associates, argued that “[t]here is no accommodation that the BOP can safely put into place that will result in Mr. Shkreli having sufficient access to Civil Counsel” in the FTC case.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]